Innovative Therapeutics Cellestia Biotech is developing first-in-class therapeutics targeting autoimmune diseases and drug-resistant cancers, presenting opportunities to collaborate with research institutions or pharmaceutical companies seeking breakthrough treatments.

Strong Funding Backing With significant investment rounds totaling over 20 million USD and strategic integration with TVM Capital, the company is financially positioned to accelerate clinical development and expand partnerships in the biotech sector.

Clinical Progress Cellestia's recent achievements in progressing CB-103 through Phase 2 trials and preclinical models for breast cancer indicate readiness for partnerships or licensing deals to accelerate product commercialization.

Focused Niche Specializing in autoimmune and multi-drug resistant cancers, Cellestia targets a high-need market segment, creating opportunities to connect with medical centers, payers, and biotech partners interested in innovative cancer therapies.

Market Visibility The company's recognition through Horizon 2020 Seal of Excellence and frequent industry news coverage enhances its credibility, making it an attractive partner for investors and collaborators seeking innovative biotech ventures.